<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01323595</url>
  </required_header>
  <id_info>
    <org_study_id>1010011319</org_study_id>
    <nct_id>NCT01323595</nct_id>
  </id_info>
  <brief_title>Effectiveness of Celecoxib After Surgical Sperm Retrieval</brief_title>
  <official_title>The Use of Celecoxib (Celebrex (c)) in Post-operative Pain Control After Microdissection Testicular Sperm Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While narcotic medication are commonly used for pain control near the time of surgery, there
      are significant side effects including constipation, nausea, risk of overdose leading to
      decreased breathing, and risk of addiction to narcotics. Our goal is to explore alternatives
      to narcotics for perioperative pain for patients undergoing sperm retrieval surgery. We have
      designed a prospective randomized clinical trial to evaluate how effective the
      anti-inflammatory medicine celecoxib(Celebrex©) is for pain control near the time of surgery.
      Celecoxib is known as a COX-2 inhibitor, a drug that belongs to the non-steroidal
      anti-inflammatory drug (NSAID) class. It is used to reduce swelling and to treat pain.

      Patients will be divided into two groups: the first group receives a celecoxib pill and the
      second group receives a sugar pill(placebo). Patients and doctors will be unaware of exactly
      which pills are given. The patient will complete questionnaires for pain level. By comparing
      the pain levels we can better understand whether celecoxib (Celebrex©) significantly
      decreases perioperative pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All consecutive patients scheduled to undergo elective, outpatient microsurgical testicular
      sperm extraction (TESE) beginning in 9/2011 will be invited for participation.
      Microdissection TESE will be performed unilaterally or bilaterally, through a midline scrotal
      incision, under general anesthesia.

      Participants will be prospectively randomized in a 1:1 ratio to receive 200 mg of celecoxib
      or placebo b.i.d. in a double-blind fashion, initiated the night prior to surgery, and
      continued for six days thereafter. The randomization sequence will be generated and
      implemented by the institutional investigational pharmacy. Placebo medication, identical to
      the study medication, will also be provided by the institutional pharmacy.

      Following surgery, all participants will be asked to complete a take-home post-operative
      questionnaire recording their maximum pain level on an 11-point visual analog scale (0-10),
      at specific time intervals over the course of the day, ranging from every six hours on
      post-operative day (POD) #1 to every 8 hours on POD #2, every 12 hours on POD #3, and every
      24 hours on POD #4 to POD #7. Patients will also record the number of 5/500 mg tablets of
      acetaminophen/hydrocodone used for supplemental pain control from POD #1 to POD #7. Thirdly,
      patients will record whether or not their pain was adequately controlled at each of the
      above-mentioned time intervals.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis demonstrated significant benefit in intervention arm
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of Pain</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>Patients will rate their pain for 7 days after surgery using an 11-point visual analog scale (0= no pain, 10=worst pain ever). Patients are asked to rate their pain up to four times a day during the post-operative period. Pain scores from each post-operative day each day will be averaged and reported as the pain score for that day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Complications</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>We will record whether there are any bleeding complications associated with treatment after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib will be given for 6 days after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill for 6 days after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 200mg PO BID x 6 days</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>Sugar pill PO BID x 6 days</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;/= 18 years old

          2. Male

          3. Scheduled to undergo microdissection testicular sperm extraction

        Exclusion Criteria:

          1. History of allergies to celecoxib (Celecoxib)

          2. Renal failure

          3. History of ulcer disease

          4. Any history of myocardial infarction

          5. Any history of stroke

          6. History of bleeding diathesis

          7. Use of aspirin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter N Schlegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Urology, Weill Cornell Medical College,</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23628190</url>
    <description>Study Abstract</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <results_first_submitted>October 29, 2013</results_first_submitted>
  <results_first_submitted_qc>June 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2014</results_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain control</keyword>
  <keyword>testicular sperm extraction</keyword>
  <keyword>sperm</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients undergoing testicular sperm extraction surgery</recruitment_details>
      <pre_assignment_details>No exclusions except allergy to treatment agent (celecoxib)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Celecoxib</title>
          <description>Celecoxib will be given for 5 days after surgery
Celecoxib : Celecoxib 200mg PO BID x 6 days</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Sugar pill for 5 days after surgery.
Sugar Pill : Sugar pill PO BID x 6 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16">Remaining subjects did not return questionnaire</participants>
                <participants group_id="P2" count="18">Remaining subjects did not return questionaire</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Celecoxib</title>
          <description>Celecoxib will be given for 6 days after surgery
Celecoxib : Celecoxib 200mg PO BID x 6 days</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Sugar pill for 6 days after surgery.
Sugar Pill : Sugar pill PO BID x 6 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="5"/>
                    <measurement group_id="B2" value="35" spread="5"/>
                    <measurement group_id="B3" value="37" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Level of Pain</title>
        <description>Patients will rate their pain for 7 days after surgery using an 11-point visual analog scale (0= no pain, 10=worst pain ever). Patients are asked to rate their pain up to four times a day during the post-operative period. Pain scores from each post-operative day each day will be averaged and reported as the pain score for that day.</description>
        <time_frame>1 week after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Treatment</title>
            <description>Patients received placebo medication</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Patients received celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Pain</title>
          <description>Patients will rate their pain for 7 days after surgery using an 11-point visual analog scale (0= no pain, 10=worst pain ever). Patients are asked to rate their pain up to four times a day during the post-operative period. Pain scores from each post-operative day each day will be averaged and reported as the pain score for that day.</description>
          <units>Analog pain scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="2"/>
                    <measurement group_id="O2" value="4" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Complications</title>
        <description>We will record whether there are any bleeding complications associated with treatment after surgery.</description>
        <time_frame>7 days after surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Treatment</title>
          <description>Patients received placebo medication</description>
        </group>
        <group group_id="E2">
          <title>Celecoxib</title>
          <description>Patients received celecoxib</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chairman, Department of Urology</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>212 746-5491</phone>
      <email>pnschleg@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

